Outcome and risk factor of immune‐related adverse events and pneumonitis in patients with advanced or postoperative recurrent non‐small cell lung cancer treated with immune checkpoint inhibitors-Reference-Cited by-同舟云学术

Outcome and risk factor of immune‐related adverse events and pneumonitis in patients with advanced or postoperative recurrent non‐small cell lung cancer treated with immune checkpoint inhibitors

Published:2020-11-17 Issue:2 Volume:12 Page:153-164
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Isono Taisuke¹^ORCID,Kagiyama Naho¹,Takano Kenji¹,Hosoda Chiaki¹,Nishida Takashi¹,Kawate Eriko¹,Kobayashi Yoichi¹,Ishiguro Takashi¹,Takaku Youtaro¹,Kurashima Kazuyoshi¹,Yanagisawa Tsutomu¹,Takayanagi Noboru¹

Affiliation:

1. Department of Respiratory Medicine Saitama Cardiovascular and Respiratory Center Saitama Japan

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.13736

Reference38 articles.

1. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

2. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

3. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

4. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

5. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. Non-bacterial cystitis caused by pembrolizumab therapy for adenocarcinoma of the lung: a case report;Frontiers in Immunology;2024-07-05

3. Treatment Strategies for Non-Small-Cell Lung Cancer with Comorbid Respiratory Disease; Interstitial Pneumonia, Chronic Obstructive Pulmonary Disease, and Tuberculosis;Cancers;2024-04-29

4. Are Immune Checkpoint Inhibitors Safe and Effective in Lung Cancer Patients with Pre-Existing Interstitial Lung Disease?;Immunotherapy;2024-03-21

5. Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors;Cancers;2024-03-20